Radius Appoints Erika Tooman as SVP / General Counsel

Boston, Mass., April 5, 2023 – Radius Health, Inc. (“Radius” or the “Company”), Radius Health (“Radius”), a specialty biopharmaceutical company dedicated to bone health and expanding access for patients, announced the appointment of Erika Tooman to the role of Senior Vice President / General Counsel, reporting to the Company’s Chief Executive Officer, Scott Briggs.

Ms. Tooman is an accomplished pharmaceutical executive and strategist and will lead the corporate legal, intellectual property and compliance teams. She has broad experience in providing valuable perspective, establishing vision, and implementing strategy to achieve business goals. She has diverse knowledge and capabilities in corporate governance, M&A, intellectual property, regulatory and compliance and is a proven leader for building and growing companies.

“Radius is dedicated to bone health around the world,” said Radius’s CEO, Scott Briggs. “I am thrilled to have Erika join my executive team, as her aligned and strategic vision increases our ability to accelerate our success in taking on this endeavor.”

“I am thrilled to join Radius at such an exciting time and to work with the leadership and investors to accelerate business priorities and capture growth opportunities,” said Ms. Tooman. “The team at Radius is extremely passionate, and I am excited to be part of our bright future.”

Prior to joining Radius, Ms. Tooman most recently SVP, General Counsel, Chief Compliance Officer & Corporate Secretary of Currax Pharmaceuticals, where she led the legal department. She is a recipient of the Healthcare Businesswomen’s Association Rising Star Award, is a registered patent attorney and is certified in healthcare compliance. Ms. Tooman earned her JD from Brooklyn Law School, Master of Arts degree in Biotechnology from Columbia University, and Bachelor of Arts degree in Biology from Franklin & Marshall College. She is deeply involved in her local community and is a member of the RWJ University Hospital Advisory Board of Directors and the Raritan Valley Community College Foundation Board of Directors.

About Radius

Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 for the treatment of men with osteoporosis at high risk for fracture.

Contact:
Sara Goldberg: Lead, Communications
Email: [email protected]
Phone: +1 (631) 379-8374